Oct 2026
Treatment sequence after first-line immunotherapy in older adults with advanced NSCLC (NEJ057).
K. Kushiro, Yoko Tsukita, T. Tozuka et al.
· International Journal of Cli... · 0 citations
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Open access
Sep 2026
Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.
INTRODUCTION First-line osimertinib monotherapy remains a standard treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although intensified regimens improve outcomes at the cost of an increased toxicity and treatment burden. We characterized pretreatment clinical f...
Masaki Ishida, T. Yamada, O. Yamaguchi et al.
· Journal of Thoracic Oncology · 0 citations